Is there a correlation between infliximab trough levels and the development of adverse events in patients with inflammatory bowel disease?

BACKGROUND/AIMS: The measurement of infliximab trough levels (IFX-TLs) in patients with inflammatory bowel disease (IBD) is performed to optimize treatment. However, the association between the development of adverse events (AEs) and IFX-TLs has not been sufficiently studied thus far. To investigate...

Descripción completa

Detalles Bibliográficos
Autores principales: Theodoraki, Eirini, Orfanoudaki, Eleni, Foteinogiannopoulou, Kalliopi, Legaki, Evangelia, Gazouli, Maria, Koutroubakis, Ioannis E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Association for the Study of Intestinal Diseases 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8566825/
https://www.ncbi.nlm.nih.gov/pubmed/32806874
http://dx.doi.org/10.5217/ir.2020.00042

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8566825/
https://www.ncbi.nlm.nih.gov/pubmed/32806874
http://dx.doi.org/10.5217/ir.2020.00042

Ejemplares similares